Placeholder Banner

Dow Jones VentureWire: BIO Report on Venture Funding for Therapeutic Innovation

February 9, 2015
Today, Brian Gormley's story - Biotech VCs Shift Away From Chronic Diseases, Report Says - highlights VC funding trends over a 10-year period.

BIO released the report today showing that venture capital is shifting away from chronic diseases and increasing for rare diseases. The report categorized $38 billion of investment across more than 1,200 companies from 2004 through 2013.

BIO's report compares five-year periods before and after the financial crisis. From 2004 through 2008, for example, venture capitalists pumped $675 million into drugs for the most common form of diabetes, Type 2. That total declined 28% to $488 million in the more recent five-year period of 2009 through 2013, the report said.

The story can be accessed here. (subscription required)